Revenue
2019
2020
2021
2022
2023
2024
2025
IceCure Medical Ltd. (ICCM)
Price$2.09Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $3.3M | $3.2M | $3.1M | $4.1M | $3.9M | $1.6M |
| Gross profit | $1.2M | $1.5M | $1.3M | $1.4M | $2.2M | $2.4M | $524,000 |
| Gross margin | 36.28% | 44.09% | 40.26% | 46.84% | 53.04% | 63.19% | 32.21% |
| Research & development | $7.4M | $7.1M | $8.3M | $9.1M | $5.9M | $3.8M | $3.0M |
| Operating expenses | $16.3M | $17.1M | $16.9M | $18.2M | $11.9M | $6.6M | $5.3M |
| Operating income | −$15.1M | −$15.7M | −$15.6M | −$16.7M | −$9.7M | −$4.1M | −$4.8M |
| Operating margin | −446.70% | −476.94% | −482.38% | −542.59% | −234.99% | −107.08% | −294.04% |
| EBITDA | −$14.8M | −$15.4M | −$15.3M | −$16.5M | −$9.6M | −$4.1M | −$4.8M |
| EBITDA margin | −437.97% | −466.85% | −472.38% | −534.55% | −231.92% | −105.46% | −292.07% |
| Net income | −$15.1M | −$15.3M | −$14.7M | −$17.0M | −$9.9M | −$3.7M | −$4.6M |
| Net profit margin | −445.61% | −465.45% | −453.76% | −550.34% | −239.13% | −96.43% | −279.72% |
| Basic EPSper basic share | $0.24 | $0.30 | $0.32 | $0.46 | $0.35 | $0.22 | $0.33 |
| Diluted EPSper diluted share | $0.24 | $0.30 | $0.32 | $0.46 | $0.35 | $0.22 | $0.33 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Shamir Eyal | 791.38K |
Peleg Meir | 400K |
Mayron Ron | 296.63K |
Tsimerman Ronen | 177.95K |
Tel-Tzure Tlalit Bussi | 170.63K |
Good Shad | 156.46K |
Levav Shay | 144.62K |
Muchnik Naum | 118.62K |
Huang Yang | 111.47K |
Dotan Merav Nir | 68.81K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Sep 29, 2026 · Quarterly data